Sentences with phrase «cancer immunotherapy combinations»

Not exact matches

U.S. drug giant Merck is paying $ 300 million in a deal possibly worth more than $ 5 billion to partner Eisai in an effort to boost its star cancer immunotherapy treatment Keytruda, which could match up well in a combination with Eisai's Lenvima.

«While we are disappointed CheckMate - 026 did not meet its primary endpoint in this broad patient population, we remain committed to improving patient outcomes through our comprehensive development program, including the ongoing Phase III CheckMate - 227 study exploring the potential of the combination of Opdivo plus [our other cancer immunotherapy] Yervoy for PD - L1 positive patients, and Opdivo plus Yervoy, or Opdivo plus chemotherapy in PD - L1 negative patients,» he added.

To achieve this goal, the cancer field is moving away from chemotherapy and towards a combination of immunotherapy and targeted therapy, an approach that is more potent and less toxic.

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression.

In addition to formulating diagnostic strategies for cancer immunotherapy agents, her team is focused on developing a deep understanding of tumor immune biology as well as mechanisms associated with immune response and immune escape in cancer patients, with the intent of generating rational strategies for the creation of combination therapies.

«Clinical trial using immunotherapy drug combinations to treat lung cancer appears safe.»

Roche has four biologic cancer immunotherapy molecules in clinical trials that could work in powerful combinations with each other or with current drugs, says William Pao, global head of oncology discovery in Basel.

«Combination immunotherapy effective for advanced prostate cancer.»

Biden has also been talking to Los Angeles, California, oncologist and billionaire Patrick Soon - Shiong, who on 11 January announced an industry - led moonshot aimed at testing in clinical trials combinations of cancer immunotherapy drugs, one of most promising new cancer treatments in recent years.

These therapies could enhance the effects of novel cancer immunotherapies when used in combination, resulting in better health outcomes for cancer patients.

To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.

Cancer immunotherapy is mainly applied in combination with chemotherapy and radiotherapy.

Combination immunotherapy with nivolumab and ipilimumab as tested in the kidney cancer study described here is already FDA - approved for treatment of melanoma, and is being tested for other cancers.

The U.S. Food and Drug Administration granted approval to the combination of two immunotherapy drugs, ipilimumab and nivolumab, for the treatment of metastatic kidney cancer.

These subtypes known as memory T cells may explain why some immunotherapies are more effective than others and potentially lead to researchers designing more effective studies using combination checkpoint blockade treatments, according to experts at The University of Texas MD Anderson Cancer Center.

«Motolimod holds considerable promise as a cancer drug, particularly as a component of combination immunotherapies.

At Thursday's Winship symposium on cancer immunotherapy, Rafi said the name of the game is now combinations, with an especially good one being PD - 1 inhibitors plus IL2.

The CRI Anna - Maria Kellen Clinical Accelerator is a unique industry - academia collaboration model designed to unlock the potential of combination cancer immunotherapies.

To meet this end, CCIR members take advantage of resources offered by MD Anderson, including the CCSG Shared Resources, Immune Monitoring Core Laboratory and GMP Cell Facility, allowing them to follow the «bench - to - beside» approach to develop and improve cancer immunotherapy in the form of cellular therapy, a vaccine or targeting antibody, either alone or in combination with conventional therapies or newly developed therapies.

A Phase 1b / 2 Open - Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

She has identified novel immune - modulating activities associated with targeted cancer drugs in preclinical models, and developed synergistic immunotherapy combinations.

If you've seen cancer immunotherapy in the news recently, you probably have heard about combination therapies.

The CRI Cancer Immunotherapy Consortium hosts its 2011 Colloquium, the first meeting of its kind to focus on Schedule and Dose in Combination Therapy.

Visit our website to find out more about the Clinical Accelerator and for information about combination therapies that came out of our 2013 Cancer Immunotherapy Consortium meeting.

Society for Immunotherapy of Cancer (SITC) Symposium Combination Cancer Immunotherapy: Expanding Clinical Success Saturday, May 5, 8:00 AM — 10:00 AM, Room 12AB Chairs: Bernard A. Fox, Earle A. Chiles Res.

Through her Clinical Team Grant, Dr. Bhardwaj and Sacha Gnjatic, Ph.D., are investigating the relationship between checkpoint immunotherapy, chemotherapy, and mutations in advanced bladder cancer, to guide vaccine development and inform combination treatment approaches.

Sharma spoke about one example of this approach: a recently launched CRI Clinical Accelerator trial testing a CD40 - based immunotherapy in combination with checkpoint immunotherapy and chemotherapy for patients with pancreatic cancer.

Additional trials utilizing this vaccine are ongoing in glioblastoma, while a vaccine and checkpoint immunotherapy combination trial is being planned for patients with bladder cancer.

The combination of rituximab (Rituxan) and the novel immunotherapy pidilizumab (CT - 011) is both active and well tolerated in follicular lymphoma patients, according to results of a phase II trial presented by Jason R. Westin, MD, of the MD Anderson Cancer Center in Houston, at the American Society of Hematology (ASH) meeting in Atlanta.

In addition to bevacizumab (Avastin ®) a targeted antibody that is already approved for cervical cancer patients, there are several other types of immunotherapies that are being evaluated for cervical cancer, including some in combination.

The team will identify genetic and epigenetic features in CAR T cells and / or cancer cells that will help predict which patients will respond to the immunotherapy, with an eventual goal of initiating clinical trials that employ a combination of approaches to therapy.

The goal is to test if targeting the vitamin D receptor will unlock the potential of immunotherapies to kill pancreatic cancer tumor cells and potentially establish a therapeutic combination for controlling advanced pancreatic cancer, extending patient survival, and reducing patient side effects.

Results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression.

Immunotherapy can be used for many types of cancer, either alone or in combination with other treatments.

A combination of complementary immunotherapy drugs brentuximab vedotin (Adcetris ®) and nivolumab (Opdivo ®) destroyed most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early - phase clinical trial led by Catherine M. Diefenbach, MD, assistant professor of medicine and director of the Clinical Lymphoma Program.

To combat the nation's third deadliest cancer, the phase 1b / 2 open - label study will explore the combination of standard chemotherapy and two immunotherapy agents: an anti-PD-1 checkpoint inhibitor and a novel antibody targeting CD40, a protein that when activated can drive the immune system to attack tumors.

In the combination study, patients receive either CMB305 combined with Genentech's cancer immunotherapy, TECENTRIQ ® (atezolizumab, anti-PD-L1), or atezolizumab alone, pursuant to a collaboration with Genentech.

«Immune checkpoint inhibitors, including PD - 1 and PD - L1 inhibitors, have provided meaningful clinical benefits for patients with cancer; however, novel immunotherapy combination treatments are needed to improve efficacy with limited additive toxicity,» said Aung Naing, MD, FACP, associate professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Hocancer; however, novel immunotherapy combination treatments are needed to improve efficacy with limited additive toxicity,» said Aung Naing, MD, FACP, associate professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, HoCancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, HoCancer Medicine, The University of Texas MD Anderson Cancer Center, HoCancer Center, Houston.

Here we describe the results of a novel type of complementary immunotherapy of cancer that is based on a combination of ketogenic diet, administration of an emulsion made of chondroitin sulfate, vitamin D3 and oleic acid and of a fermented milk and colostrum product.

Each type of cancer requires individual care and may include a combination of treatment therapies such as surgery, chemotherapy, radiation, cryosurgery (freezing), hyperthermia (heating) or immunotherapy.

Sometimes cancer is curable - especially if caught early, but often it is a chronic disease that is managed by a combination of surgery, chemotherapy, radiation and some new innovative treatments like antibody therapy, immunotherapy, vaccines, cyberknife therapy, etc..

Typically, cancers may be treated with combinations of surgery, chemotherapy, radiation therapy, and sometimes immunotherapy.